Bicara Therapeutics (BCAX) Other Non-Current Assets (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Other Non-Current Assets data on file, last reported at $6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 4.14% year-over-year to $6.9 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (up 4.14% YoY), and the FY2025 full-year result was $6.9 million, up 4.41% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $6.9 million, roughly flat from $6.9 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $7.8 million in Q3 2025 and bottomed at $2.1 million in Q4 2023.
• The 4-year median for Other Non-Current Assets is $6.7 million (2025), against an average of $5.7 million.
• The widest annual swing landed in 2025, when Other Non-Current Assets soared 268.56%; it then rose 4.14% in 2026.
• A 4-year view of Other Non-Current Assets shows it stood at $2.1 million in 2023, then soared by 216.05% to $6.6 million in 2024, then gained by 4.41% to $6.9 million in 2025, then changed by 0.0% to $6.9 million in 2026.
• The last three Other Non-Current Assets figures came in at $6.9 million (Q1 2026), $6.9 million (Q4 2025), and $7.8 million (Q3 2025), per Business Quant data.

Peer Comparison